PT  - JOURNAL ARTICLE
AU  - Huanhuan Gao
AU  - Jiening Xiao
AU  - Qiang Sun
AU  - Huixian Lin
AU  - Yunlong Bai
AU  - Long Yang
AU  - Baofeng Yang
AU  - Huizhen Wang
AU  - Zhiguo Wang
TI  - A Single Decoy Oligodeoxynucleotides Targeting Multiple Oncoproteins Produces Strong Anticancer Effects
AID  - 10.1124/mol.106.024273
DP  - 2006 Nov 01
TA  - Molecular Pharmacology
PG  - 1621--1629
VI  - 70
IP  - 5
4099  - http://molpharm.aspetjournals.org/content/70/5/1621.short
4100  - http://molpharm.aspetjournals.org/content/70/5/1621.full
SO  - Mol Pharmacol2006 Nov 01; 70
AB  - Cancer in general is a multifactorial process. Targeting a single factor may not be optimal in therapy, because single agents are limited by incomplete efficacy and dose-limiting adverse effects. Combination pharmacotherapy or “drug cocktail” therapy has value against many diseases, including cancers. We report an innovative decoy oligodeoxynucleotide (dODN) technology that we term complex decoy oligodeoxynucleotide (cdODNs) in which multiple cis elements are engineered into single dODNs attacking multiple target transcription factors, mimicking the drug cocktail approach. We designed dODNs targeting NF-κB, E2F, and Stat3 separately and a cdODN targeting NF-κB, E2F, and Stat3 concomitantly. We evaluated effects of this cdODN on expression of cancer-related genes, viability of human cancer cell lines, and in vivo tumor growth in nude mice. The cdODN targeting all NF-κB, E2F, and Stat3 together demonstrated enhancement of efficacy of more than 2-fold and increases in potency of 2 orders of magnitude compared with each of the dODNs or the combination of all three dODNs. The cdODN also showed earlier onset and longer-lasting action. Most strikingly, the cdODN acquired the ability to attack multiple molecules critical to cancer progression via multiple mechanisms, leading to elimination of regression. Real-time reverse transcription-polymerase chain reaction revealed that the cdODNs knocked down expression of the genes regulated by the target transcription factors. The cdODN strategy offers resourceful combinations of varying cis elements for concomitantly targeting multiple molecules in cancer biological processes and opens the door to “one-drug, multiple-target” therapy for a broad range of human cancers. The American Society for Pharmacology and Experimental Therapeutics